Pharmacokinetics of tiludronate in horses: A field population study.
Authors: Popot M A, Jacobs M, Garcia P, Loup B, Guyonnet J, Toutain P L, Bailly-Chouriberry L, Bonnaire Y
Journal: Equine veterinary journal
Summary
# Tiludronate Detection Times in Competition Horses: A Field-Based Pharmacokinetic Study Tiludronate, a bisphosphonate commonly used to treat bone conditions in racing and sport horses, is a controlled substance in equine competition, yet detection guidelines have largely relied on data from healthy experimental animals rather than treated populations. Researchers administered 1 mg/kg tiludronate intravenously to 39 clinically lame horses with diagnosed bone conditions under field conditions, collecting 93 blood samples across days 10–50 post-treatment and analysing plasma concentrations using high-performance liquid chromatography coupled with mass spectrometry; population pharmacokinetic modelling and Monte Carlo simulations then generated evidence-based detection windows. The study revealed meaningful differences in drug clearance between healthy experimental horses and working horses requiring treatment, with training intensity significantly influencing plasma concentrations—findings that substantially alter the predicted detection times compared to previous laboratory-based estimates. These results provide racing and sport authorities with pharmacokinetic data reflecting genuine clinical populations, enabling more accurate and fair detection thresholds that account for the physiological variables encountered in practice. The methodology also establishes a valuable framework for future medication control guidelines: deriving detection times directly from target horse populations rather than controlled experimental settings yields recommendations with genuine real-world applicability, improving both the science and equity of doping control programmes across equestrian sports.
Read the full abstract on PubMed
Practical Takeaways
- •If using tiludronate for bone conditions, be aware that detection times for doping control vary based on individual horse factors including training level, not just dose
- •This study provides evidence that field conditions produce different pharmacokinetics than experimental settings, so racing/competition authorities should use field-derived detection windows rather than laboratory data
- •Tiludronate clearance appears to be influenced by horse training status, which may affect both therapeutic efficacy and regulatory compliance timelines
Key Findings
- •Pharmacokinetic differences exist between healthy experimental horses and field-treated horses receiving tiludronate
- •Level of training significantly affects plasma tiludronate concentrations in treated horses
- •Population pharmacokinetic modelling enabled estimation of detection times for doping control screening at multiple potential limits
- •Field-based population approach provides more relevant detection times than experimental studies for racing and sports authorities